Compare RCAT & OCUL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RCAT | OCUL |
|---|---|---|
| Founded | 2002 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Wholesale Distributors | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.1B |
| IPO Year | 2017 | 2014 |
| Metric | RCAT | OCUL |
|---|---|---|
| Price | $11.14 | $9.66 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | $20.00 | ★ $23.56 |
| AVG Volume (30 Days) | ★ 9.2M | 2.9M |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $17,836,382.00 | $1,990,000.00 |
| Revenue This Year | $271.60 | $7.93 |
| Revenue Next Year | $41.21 | $96.07 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 79.95 | 3.48 |
| 52 Week Low | $5.12 | $6.23 |
| 52 Week High | $18.78 | $16.44 |
| Indicator | RCAT | OCUL |
|---|---|---|
| Relative Strength Index (RSI) | 41.41 | 58.09 |
| Support Level | $11.01 | $8.36 |
| Resistance Level | $13.69 | $9.91 |
| Average True Range (ATR) | 0.86 | 0.41 |
| MACD | -0.11 | 0.03 |
| Stochastic Oscillator | 15.69 | 78.85 |
Red Cat Holdings Inc is a drone technology company integrating robotic hardware and software for military, government, and commercial operations. Red Cat's suite of solutions includes the Arachnid family of ISR and precision strike drones, which includes the Black Widow, a small unmanned ISR system; and WEB (Warfighter Electronic Bridge) GCS, designed to command and control an entire drone family of systems for military operations. Its other offerings include Edge 130 Blue drone systems, Trichon, a fixed-wing VTOL for extended endurance and range, and FANG FPV drones optimized for military operations with precision strike capabilities.
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.